Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy

E. Mezeiova, J. Korabecny, V. Sepsova, M. Hrabinova, P. Jost, L. Muckova, T. Kucera, R. Dolezal, J. Misik, K. Spilovska, NL. Pham, L. Pokrievkova, J. Roh, D. Jun, O. Soukup, D. Kaping, K. Kuca,

. 2017 ; 22 (8) : . [pub] 20170728

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024753

Grantová podpora
NV15-30954A MZ0 CEP - Centrální evidence projektů

Tacrine (THA), the first clinically effective acetylcholinesterase (AChE) inhibitor and the first approved drug for the treatment of Alzheimer's disease (AD), was withdrawn from the market due to its side effects, particularly its hepatotoxicity. Nowadays, THA serves as a valuable scaffold for the design of novel agents potentially applicable for AD treatment. One such compound, namely 7-methoxytacrine (7-MEOTA), exhibits an intriguing profile, having suppressed hepatotoxicity and concomitantly retaining AChE inhibition properties. Another interesting class of AChE inhibitors represents Huprines, designed by merging two fragments of the known AChE inhibitors-THA and (-)-huperzine A. Several members of this compound family are more potent human AChE inhibitors than the parent compounds. The most promising are so-called huprines X and Y. Here, we report the design, synthesis, biological evaluation, and in silico studies of 2-methoxyhuprine that amalgamates structural features of 7-MEOTA and huprine Y in one molecule.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024753
003      
CZ-PrNML
005      
20201104095942.0
007      
ta
008      
180709s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules22081265 $2 doi
035    __
$a (PubMed)28788095
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mezeiova, Eva $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. eva.mezeiova@gmail.com. National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic. eva.mezeiova@gmail.com.
245    10
$a Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy / $c E. Mezeiova, J. Korabecny, V. Sepsova, M. Hrabinova, P. Jost, L. Muckova, T. Kucera, R. Dolezal, J. Misik, K. Spilovska, NL. Pham, L. Pokrievkova, J. Roh, D. Jun, O. Soukup, D. Kaping, K. Kuca,
520    9_
$a Tacrine (THA), the first clinically effective acetylcholinesterase (AChE) inhibitor and the first approved drug for the treatment of Alzheimer's disease (AD), was withdrawn from the market due to its side effects, particularly its hepatotoxicity. Nowadays, THA serves as a valuable scaffold for the design of novel agents potentially applicable for AD treatment. One such compound, namely 7-methoxytacrine (7-MEOTA), exhibits an intriguing profile, having suppressed hepatotoxicity and concomitantly retaining AChE inhibition properties. Another interesting class of AChE inhibitors represents Huprines, designed by merging two fragments of the known AChE inhibitors-THA and (-)-huperzine A. Several members of this compound family are more potent human AChE inhibitors than the parent compounds. The most promising are so-called huprines X and Y. Here, we report the design, synthesis, biological evaluation, and in silico studies of 2-methoxyhuprine that amalgamates structural features of 7-MEOTA and huprine Y in one molecule.
650    _2
$a acetylcholinesterasa $7 D000110
650    _2
$a Alzheimerova nemoc $x farmakoterapie $7 D000544
650    _2
$a aminochinoliny $x chemická syntéza $x chemie $x farmakologie $7 D000634
650    _2
$a vazebná místa $7 D001665
650    _2
$a hematoencefalická bariéra $x metabolismus $7 D001812
650    _2
$a butyrylcholinesterasa $7 D002091
650    _2
$a katalytická doména $7 D020134
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cholinesterasové inhibitory $x chemie $x farmakologie $7 D002800
650    _2
$a racionální návrh léčiv $7 D015195
650    12
$a objevování léků $7 D055808
650    _2
$a aktivace enzymů $x účinky léků $7 D004789
650    _2
$a heterocyklické sloučeniny tetra- a více cyklické $x chemie $x farmakologie $7 D006576
650    _2
$a lidé $7 D006801
650    _2
$a hydrolýza $7 D006868
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární konformace $7 D008968
650    _2
$a molekulární struktura $7 D015394
650    _2
$a permeabilita $7 D010539
650    _2
$a vazba proteinů $7 D011485
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a takrin $x analogy a deriváty $x chemie $x farmakologie $7 D013619
655    _2
$a časopisecké články $7 D016428
700    1_
$a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. korabecny.jan@gmail.com. National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic. korabecny.jan@gmail.com.
700    1_
$a Sepsova, Vendula $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. vsepsova@gmail.com. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. vsepsova@gmail.com.
700    1_
$a Hrabinova, Martina $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. martina.hrabinova@unob.cz. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. martina.hrabinova@unob.cz.
700    1_
$a Jost, Petr $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. petr.jost@unob.cz. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. petr.jost@unob.cz.
700    1_
$a Muckova, Lubica $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. lubica.muckova@unob.cz.
700    1_
$a Kucera, Tomas $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. kucera-t@email.cz.
700    1_
$a Dolezal, Rafael $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. rafael.dolezal@fnhk.cz.
700    1_
$a Misik, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. honzamisik@seznam.cz. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. honzamisik@seznam.cz.
700    1_
$a Spilovska, Katarina $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. k.spilovska@gmail.com. National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic. k.spilovska@gmail.com.
700    1_
$a Pham, Ngoc Lam $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. phama92@gmail.com. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. phama92@gmail.com.
700    1_
$a Pokrievkova, Lucia $u Department of Organic and Biorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. elpokrievkova@gmail.com.
700    1_
$a Roh, Jaroslav $u Department of Organic and Biorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. rohj@faf.cuni.cz.
700    1_
$a Jun, Daniel $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. daniel.jun@unob.cz. Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic. daniel.jun@unob.cz.
700    1_
$a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. ondrej.soukup@fnhk.cz. National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic. ondrej.soukup@fnhk.cz.
700    1_
$a Kaping, Daniel $u National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic. Daniel.Kaping@nudz.cz.
700    1_
$a Kuca, Kamil $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. kamil.kuca@fnhk.cz. Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic. kamil.kuca@fnhk.cz.
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 22, č. 8 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28788095 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20201104095939 $b ABA008
999    __
$a ok $b bmc $g 1316884 $s 1021674
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 22 $c 8 $e 20170728 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
GRA    __
$a NV15-30954A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace